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Abstract. Galantamine improved symptoms in Alzheimer’s disease (AD) patients after 5 to 6 months of treatment. To examine
long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive
deterioration. It consisted of two phases: an open label (OL) phase (12 months), followed by a double blind, randomized,
placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and
titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of <4 points
on AD Assessment Scale-cognitive subscale (ADAS-cog)/11 was recorded at the end of the OL phase. The differences between
galantamine and placebo in time to dropout were estimated using the Cox proportional hazard model. 47.4% of galantamine
and 31.7% of placebo subjects completed the double blind phase. Placebo subjects were more likely to discontinue prematurely
than galantamine subjects for any reason (hazard ratio [HR] 1.76, 95% confidence interval [CI] 1.10–2.81, p = 0.02), or lack
of efficacy (HR 1.80, 95% CI 1.02–3.18, p = 0.04); no statistically significant difference was seen for a change in ADAS-cog
≥4 between treatment groups (HR 1.66, 95% CI 0.78–3.54, p = 0.19). Subjects who responded to 12 months of galantamine
treatment benefited from continued drug therapy for up to 36 months. Galantamine was effective in delaying time to cognitive
deterioration in subjects with mild to moderate AD. Treatment was generally safe and well tolerated.
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INTRODUCTION
A systematic review of galantamine in Alzheimer’s
disease (AD) and mild cognitive impairment, includ-
ing 10 randomized, placebo controlled trials with a
duration of longer than 10 weeks and a total of 6805
subjects, confirmed a significant treatment effect of
galantamine over placebo with regards to cognition,
activities of daily living, and behavioral symptoms at
doses between 16 to 24 mg per day [1].
Results from long-term open label extension trials
suggest that a subgroup of AD patients treated with
galantamine remained stable in the cognitive domain
for up to 14 months [2] and that a third of treated
patients showed very slow symptom progression up
to 48 months [3]. However, most well controlled clini-
cal trials present treatment outcomes at 5 to 6 months,
therefore they are limited in the information that can be
provided about long-term effects in a chronic disease
such as AD. In addition, healthcare decision makers
have acknowledged the beneficial outcomes of galan-
tamine but raised doubts about long term effectiveness
[4].
In order to examine long-term outcomes in more
depth, a clinical trial was conducted to assess whether
continuing treatment with galantamine for up to
24 months might result in delaying the cognitive dete-
rioration associated with AD, compared with cessation
of treatment after 12 months. At the time of designing
the study, there were no placebo controlled long-term
studies available to demonstrate efficacy, safety, and
tolerability of galantamine over one year of treatment.
METHODS
Subjects
This multicenter study was conducted at 29 study
sites in Italy between July 2001 (first subject in) and
November 2005 (last subject out).
Subjects were eligible to participate if they were out-
patients, aged ≥50 years, and had received a diagnosis
of probable AD according to the National Institute of
Neurologic and Communicative Disorders and Stroke
and AD and Related Disorders Association (NINCDS-
ADRDA), with mild to moderate cognitive impairment
(Mini Mental State Examination [MMSE] score from
11 to 24). Key exclusion criteria were: presence of a
neurodegenerative disorder other than AD, any serious
and clinically significant illness, history of previous
cerebral infarction, or the use of acetylcholinesterase
inhibitors within 3 months before inclusion.
Subjects had to be withdrawn from the study if they
showed a cognitive deterioration (≥4 points of the AD
Assessment Scale-cognitive subscale [ADAS-cog]/11
score) at the end of the open label phase or during the
double blind phase; they or their caregiver withdrew
consent; or if the randomization code was broken. Sub-
jects could also have been withdrawn from the study if
a serious adverse event (SAE) occurred or if the inves-
tigator considered it to be in the best interest of the
patient.
Anti-depressants, mood stabilizers, and cholin-
omimetics were not allowed during the trial. Anti-
dementia agents other than study drug were not allowed
during the trial: cholinesterase inhibitors (donezepil,
tacrine, rivastigmine), nootropics.
All subjects and their caregivers provided written
informed consent. The trial was carried out in accor-
dance with guidelines on good clinical practice from
the International Conference on Harmonisation (ICH)
of technical requirements for registration of pharma-
ceuticals for human use and was approved by the local
ethics committee of each center.
Study design
Overall study duration was 36 months and encom-
passed two phases: a 12 month open label phase
followed by a randomized, double blind, placebo
controlled withdrawal phase that lasted for up to
24 months.
Open label phase
During the first four weeks of the open label phase,
subjects were titrated from 4 mg bid (8 mg/day) of
immediate release galantamine to 8 mg bid (16 mg/
day). Tablets were taken in the morning and in the
evening, preferably with a meal. Subjects whose
cognitive deterioration was less than 4 points in
ADAS-cog/11 score at the end of the open label phase
compared with the baseline score were eligible to
enter the double blind phase.
Double blind phase
During the double blind phase, subjects received
galantamine tablets 8 mg bid (16 mg/day) or two
placebo tablets, one in the morning and one in the
evening. Drug accountability was checked at each visit.
The double blind phase lasted up to 24 months or
until subjects met the withdrawal criteria (change in
ADAS-cog score ≥4 points compared with the score
at the end of the open label phase). If subjects had a
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change in ADAS-cog score ≥4, the change had to be
confirmed after one month; if subjects met the with-
drawal criteria they were withdrawn from the study. If
the change was not confirmed after one month, sub-
jects continued their participation in the trial. The flow
of participants through the study is shown in Fig. 1.
Randomization and blinding
At the beginning of the open label phase, subjects
were given a subject number corresponding to a com-
puter generated randomization code. Subjects were
randomly allocated to treatment 1 : 1 (galantamine :
OPEN LABEL PHASE 
N = 254 Safety population 
N = 244 ITT population
Withdrawn in open label phase:
Sudden death n = 1 (0.4%) 
Adverse events n = 37 (14.6%) 
Personal reasons n = 26 (10.2%) 
Patient uncooperative n = 9 (3.5%) 
Poor efficacy n = 1 (0.4%) 
Other n = 4 (1.6%) 
176 patients completed 1 year 
open label phase 
Not entered double blind phase: 
Poor efficacy n = 29 (16.5%) 
Consent withdrawn n = 6 (3.4%) 
Adverse events n = 1 (0.6%) 
Other n = 1 (0.6%) 
DOUBLE BLIND PHASE 
N = 139 Safety population
Galantamine (N = 76)
N = 69 ITT population 
Placebo (N = 63) 
N = 57 ITT population 
Withdrawn in double blind phase:
Personal reasons n = 4 (5.3%) 
Adverse events n = 7 (9.2%) 
Poor efficacy n = 23 (30.3%)  
Poor adherence n = 2 (2.6%) 
Patient uncooperative n = 2 (2.6%) 
Other n = 2 (2.6%) 
Withdrawn in double blind phase: 
Personal reasons n = 7 (11.1%)
Adverse events n = 3 (4.8%) 
Poor efficacy n = 26 (41.3%) 
Poor adherence n = 1 (1.6%) 
Other n = 7 (11.1%) 
36 (47.4%) completed 2 year double blind phase 
galantamine group 
19 (30.2%) completed 2 year double blind phase
placebo group 
Fig. 1. Flow of participants through the study.
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placebo). The randomization code was generated by
Janssen Pharmaceutica, Beerse, Belgium. Randomiza-
tion was balanced between the centers. Each study
center received trial medication in blocks of 4 and
assigned subject numbers consecutively starting with
the lowest available number. Trial medication was pro-
vided by Janssen Cilag SpA.
For the double blind phase, centers received boxes
containing 27 blisters of 14 tablets each. It was not pos-
sible to distinguish boxes containing active drug from
those containing placebo. Galantamine and placebo
tablets were identical in appearance, taste, and smell.
Assessments
During the open label phase, subjects were assessed
at baseline, 1, 4, 7, and 12 months (end of open label
phase). The double blind phase started at 12 months
and subjects were also assessed at 18, 24, 30, and
36 months (end of double blind phase). The following
assessments were conducted throughout the study:
 Cognitive functions measured using ADAS-cog/
11 (total score ranging from 0 ‘no impairment’
to 70 ‘severe impairment’)
 Clinical Interview Based Impression of Changes-
Plus Caregiver Input (CIBIC-plus; scores range
from 1 ‘very much improved’ to 7, ‘very much
worsened’)
 Adverse events (AEs) were spontaneously
recorded by subjects or their caregivers
 Hematology, biochemistry, and urinalysis clini-
cal laboratory tests
 Vital signs, physical examination, body weight,
and cardiovascular safety.
Statistical methods
Sample size calculation
The sample size was calculated based on an ability
to have 90% power to detect a difference between the
treatment groups at a significance level of 5% if the
median deterioration time was 3 months and 6 months
in the placebo and galantamine groups respectively,
assuming a 2 year follow-up period. This required 100
patients (50 per group). To allow for an expected
dropout rate of 40% during the open label phase of
the study and similar numbers of losses to follow-up
during the double blind phase, the study planned to
recruit an initial total of 255 patients.
Statistical analysis
For the open label phase, the intent-to-treat (ITT)
population for the efficacy analysis was defined as all
enrolled subjects known to have taken at least one dose
of study drug and who attended at least any post base-
line visit. The safety population for the open label
phase was defined as all enrolled subjects known to
have taken at least one dose of study drug.
The analysis of ADAS-cog/11 for the open label
phase was done according to an analysis of variance
(ANOVA) with repeated measures. Multiple compar-
isons versus baseline values were done according to
Bonferroni’s correction and 95% confidence intervals
(95% CIs) of the difference versus baseline mean were
calculated.
The risk of showing a difference in ADAS-cog/11
score ≥4 points in comparison with the baseline value
after one year of galantamine treatment was analyzed
according to a logistic regression model, where ADAS-
cog/11 score at baseline, gender, age, and MMSE were
used as independent variables. The dependent variable
was the endpoint variable: a difference of ADAS-
cog/11 score ≥4 points in comparison with the baseline
score.
For the double blind phase, the ITT population for
the efficacy analysis was defined as all randomized
subjects known to have taken at least one dose of
blinded study medication and who completed at least
one ADAS-cog/11 score. The safety population for the
double blind phase was defined as all enrolled subjects
known to have taken at least one dose of blinded study
medication.
The primary endpoint was the time to deterioration,
defined as deterioration in the ADAS-cog/11 score of
≥4 points relative to the start of the double blind phase,
which had to be confirmed after one month. Patients
meeting that criterion were withdrawn from the study.
The difference between treatment groups in the time to
deterioration was assessed using the Cox proportional
hazards model. Patients who completed the study were
censored at the time of study completion.
Patients who withdrew from the study prematurely
were analyzed in three ways: by dropout for any rea-
son, by dropout due to lack of efficacy, and by dropout
due to the strict criteria of deterioration of ≥4 points in
ADAS-cog/11. For dropout for any reason, all patients
who withdrew from the study for any reason were con-
sidered to have deteriorated. Regarding dropout due
to lack of efficacy, all patients who withdrew from
the study for any lack of efficacy reason (including
the subjective impression of the caregiver or general
practitioner and deterioration of ≥4 points in ADAS-
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cog/11) were considered to have deteriorated; dropouts
for other reasons than lack of efficacy were censored
at dropout. For dropout due to ADAS-cog/11 deteri-
oration, all patients who withdrew from the study for
confirmed deterioration of ≥4 points in the ADAS-
cog/11 score were considered to have deteriorated, and
patients who withdrew for other reasons were censored
at the time of dropout.
RESULTS
Demographics
Two hundred and fifty four subjects entered the
study. Demographic and clinical characteristics for all
subjects are presented in Table 1. At baseline, mean
MMSE score was 18.9 ± 3.6 and mean ADAS-cog/11
score was 24.7 ± 9.3. The most common co-morbidity
was hypertension followed by diabetes.
During the open label phase, 75 subjects (29.5%)
did not receive concomitant treatment other than study
drug, while the remaining 179 subjects (70.5%) were
treated with at least one concomitant drug. During
Table 1
Demographic and clinical data at baseline (for all subjects who
entered the open label phase) and at month 12 (for subjects who
entered the double blind phase)
Characteristics Open label Double blind
phase (baseline) phase (month 12)
Galantamine Placebo
(n = 254) (n = 76) (n = 63)
Demographic characteristics
Age (mean, years) 74.2 74.5 74.4
Gender (% female) 61.4 64.5 54.0
Body mass index 24.6 24.8a 24.9b
(mean)
Education (n [%])
Primary school 180 (70.9) 54 (71.1) 45 (71.4)
Secondary lower 28 (11.0) 9 (11.8) 8 (12.7)
school
Secondary upper 33 (13.0) 12 (15.8) 8 (12.7)
school
University 13 (5.1) 1 (1.3) 2 (3.2)
Concomitant 64.6 77.6 73.0
disease (%)
Clinical characteristics
MMSE score
Mean ± SD 18.9 ± 3.6 – –
Median 19.6 – –
ADAS-cog/11 score
Mean ± SD 24.7 ± 9.3 20.4 ± 8.8c 23.0 ± 8.7c
Median 23.0 19.4c 22.3c
MMSE, Mini Mental State Examination; ADAS-cog, Alzheimer’s
Disease Assessment Scale-cognitive subscale; SD, standard devia-
tion. a n = 75; b n = 62; cADAS-cog/11 score at start of double blind
phase. –, not applicable.
the double blind phase, 23 subjects (30.7%) in the
galantamine group and 20 subjects (31.7%) in the
placebo group did not receive concomitant treatment
other than the study drug. The most commonly admin-
istered concomitant medications during both phases of
the study were antiinflammatory and analgesic agents.
During the open label phase and for the galantamine
group in the double blind phase, the second most
common were antihypertensive drugs and the third
most common were central nervous system agents.
For the placebo group, the second most common were
central nervous system agents and the third most com-
mon were antihypertensive drugs. During the double
blind phase, the most commonly received central ner-
vous system agents were atypical antipsychotics and
benzodiazepines in the galantamine group and atypi-
cal antipsychotics and antidepressants in the placebo
group. Antipsychotic use was comparable between the
treatment groups (6 patients in the galantamine group
and 9 patients in the placebo group). Anti-depressants
were contraindicated during the study; however, very
few patients received these medications (3 patients in
each group).
Reasons for withdrawal from both phases of the
study are given in Fig. 1. During the open label
phase, the majority of withdrawals were due to AEs
(37 subjects [14.6%]) followed by personal reasons
(26 subjects [10.2%]). During the double blind phase,
the most common reason for withdrawal from the study
was due to poor efficacy (i.e., the ‘lack of efficacy’
reason for withdrawal which included the subjective
impression of the caregiver or general practitioner and
confirmed deterioration of ≥4 points in ADAS-cog/11)
for both the galantamine (23 subjects [30.3%]) and
placebo (26 subjects [41.3%]) groups.
Efﬁcacy results
Open label phase
One hundred and seventy six subjects completed the
open label phase. Cognitive functions improved sig-
nificantly (measured using the ADAS-cog/11 scale)
with galantamine treatment at month 7 relative to base-
line (from 24.1 ± 8.7 to 22.9 ± 9.6, difference = –1.2,
95% CI –2.3 to –0.1, p < 0.01). Scores were similar
to baseline values at the end of the open label phase
(month 12) (mean score at baseline = 24.1 ± 8.7, mean
score at month12 = 24.7 ± 11.3, 95% CI –0.5 to 1.7,
p = 0.16). At the end of the open label phase (month
12), CIBIC-plus score improved in 34.3% of subjects,
was unchanged in 30.9%, and worsened in 34.9% com-
pared with baseline.
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Regression analysis of the risk of showing a differ-
ence in ADAS-cog/11 score ≥4 points in comparison
with the baseline value after one year of galantamine
treatment showed a significant influence (p < 0.01) of
MMSE score on the probability of showing a differ-
ence in ADAS-cog/11 score ≥4. The higher the MMSE
score, the lower the probability of cognitive decline
(change in ADAS-cog score ≥4).
One hundred and forty one of the 176 subjects who
completed the open label phase were responders.
Double blind phase
One hundred and thirty nine of the 141 responders
entered the double blind phase of the study and were
randomly allocated to galantamine (76 subjects) or
placebo (63 subjects). 36 subjects (47.4%) in the galan-
tamine group and 19 subjects (30.2%) in the placebo
group completed the double blind phase without show-
ing a change in ADAS-cog score ≥4 points.
One hundred and twenty six of the 139 subjects
(69 galantamine subjects and 57 placebo subjects) who
entered the double blind phase were included in
the final efficacy analysis (ITT population). Thirteen
subjects (9.4%) were not included in the ITT popula-
tion because they dropped out before ADAS-cog/11
could be evaluated in the double blind phase. Reasons
for dropout were: sudden death in one subject with
myocardial infarction (not considered related to study
treatment), SAEs in three subjects (acute lymphoma
resulting in death, cerebral hemorrhage resulting in
death, and endometrial cancer; none was considered
related to study treatment), poor efficacy according to
caregiver or private physician for one subject, an AE
(depression, not considered related to study drug) in
one subject, two subjects were not cooperative, four
subjects withdrew owing to subjects reasons, and one
subject was lost to follow-up.
Placebo treated subjects were more likely to discon-
tinue the study prematurely than galantamine treated
subjects for any reason (hazard ratio [HR] 1.76, 95%
CI 1.10–2.81, p = 0.02, Table 2 and Fig. 2a) or due to
lack of efficacy (HR 1.80, 95% CI 1.02–3.18, p = 0.04,
Table 2 and Fig. 2b). No statistically significant dif-
Table 2
Cox regression analysis for dropout for any reason, owing to lack of
efficacy, and owing to a change in ADAS-cog ≥4
Reason for dropout Dropouts Hazard Lower Upper p
(n) ratio 95% CI 95% CI
Any reason 71 1.76 1.10 2.81 0.02
Lack of efficacy 48 1.80 1.02 3.18 0.04
Change in ADAS-cog ≥4 27 1.67 0.78 3.54 0.19
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive sub-
scale; CI, confidence interval.
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Fig. 2. a) Kaplan-Meier survival curve, dropout for any reason.
b) Kaplan-Meier survival curve, dropout due to lack of efficacy.
c) Kaplan-Meier survival curve, dropout due to a change in ADAS-
cog ≥4.
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ference was seen in the likelihood of premature study
discontinuation due to a change in ADAS-cog ≥4
between placebo and galantamine treated subjects (HR
1.66, 95% CI 0.78–3.54, p = 0.19, Table 2 and Fig. 2c).
Median time to dropout was 401 days and 589 days
in the placebo group for dropout for any reason and
dropout for lack of efficacy, respectively. Median
time to dropout was not reached in the active group
for either measure because less than 50% of subjects
dropped out, therefore it was not possible to calculate
median time to dropout. Median time to dropout was
also not reached in either group for dropout owing to
a change in ADAS-cog/11 score ≥4 points.
No difference was seen between treatment groups
concerning mean values of the CIBIC-plus scale.
Safety and tolerability
Open label phase
A summary of AEs is presented in Table 3. One hun-
dred and twenty eight subjects (50.4%) experienced
252 treatment emergent AEs (TEAEs). For 51 subjects
(20.1%), the TEAE was considered to be treatment
related, as judged by the investigator. Thirty one sub-
jects (12.2%) experienced an SAE. The most frequent
TEAEs, summarized by system organ class and indi-
vidual TEAEs that occurred in > 2% of subjects, and
their relationship to study drug are presented in Table 4.
The most frequent TEAEs were: gastrointestinal dis-
orders (21.3%), nervous system disorders (9.8%), and
psychiatric disorders (19.7%).
Thirty eight subjects (15%) discontinued prema-
turely during the open label phase. A total of four
deaths occurred during the open label phase, none was
considered related to study drug. One subject was hos-
pitalized due to acute dyspnea and diffuse lung edema
and died due to bronchopneumonia and respiratory
failure. Other reported causes of death were: seri-
ous scald complicated by bronchopneumonia, acute
leukemia, and Creutzfeldt-Jakob disease (confirmed
pathologically at autopsy). One subject, who was not
eligible to enter the double blind phase (ADAS-cog/11
≥4), died after completion of the open label phase due
to a systemic infection and a concomitant history of
prostatic cancer. This death was not included in the 38
subjects who discontinued the open label phase.
No clinically relevant changes were observed in
electrocardiogram (ECG) or laboratory variables.
Double blind phase
A summary of AEs is presented in Table 3. Twenty
six subjects (34%) in the galantamine group experi-
enced 35 TEAEs and 17 subjects (27%) in the placebo
Table 3
Summary of adverse events
Open label Double blind phase
phase Galantamine Placebo
n (%) n (%) n (%)
Subjects with at least 128 (50.4) 26 (34.1) 17 (27.0)
a treatment emergent AE
Subjects with a treatment 51 (20.1) 2 (2.6) 4 (6.3)
related AE, as judged
by the investigator
Subjects with an AE that led 38 (15.0) 8 (10.5) 4 (6.3)
to study discontinuation
Proportion of subjects that 31 (12.2) 11 (14.5) 4 (6.3)
experienced an SAE
AE, adverse event; SAE, serious adverse event.
group experienced 30 TEAEs. TEAEs were considered
to be treatment related by the investigator in 2 subjects
(2.6%) in the galantamine group and 4 subjects (6.3%)
in the placebo group. 11 subjects (14.5%) in the galan-
tamine group and 4 subjects (6.3%) in the placebo
group experienced an SAE. The most frequent TEAEs
by system organ class and individual TEAEs that
occurred in > 2% of subjects and their relationship to
treatment are presented in Table 4.
Discontinuation due to an AE occurred in 8 subjects
(10.5%) and 4 subjects (6.4%) in the galantamine
and placebo groups, respectively. Seven subjects died
and the following causes of death were reported in
the galantamine group: sudden death in 2 subjects
(1 patient with previous myocardial infarction and
1 patient with a recent hip fracture), cerebral hemor-
rhage in 1 patient, suspected lymphoid leukemia in 1
patient, and gastric carcinoma in 1 patient; causes of
death in the placebo group were: cerebral hemorrhage
in 1 patient and 1 patient had a cerebral ischemic event
with aphasia and dysphasia. None of the deaths during
the double blind phase was considered to be treatment
related.
No clinically relevant changes in ECG or laboratory
variables were observed.
DISCUSSION
The results of this study suggest that galantamine
treated subjects stayed on treatment longer than
placebo treated subjects and that galantamine was suc-
cessful in maintaining patients on treatment for an
additional 24 months without a significant decline in
cognitive deterioration, as defined in this study. In fact,
subjects treated with placebo were more likely to dis-
continue prematurely than subjects treated with galan-
tamine, for any reason (HR 1.76, 95% CI 1.10–2.81,
p = 0.02) or lack of efficacy (HR 1.80, 95% CI
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Table 4
Most frequent adverse events in any system organ class and any individual adverse event that occurred in >2% of subjects with relationship to
treatment
System organ class Adverse event Open label phase Double blind phase
n (%) Galantamine n (%) Placebo n (%)
Not related Related Not related Related Not related Related
Cardiac disorders All 7 (2.8) 2 (0.8) 2 (2.6) 0 0 1 (1.6)
Gastrointestinal disorders All 16 (6.3) 38 (15.0) 1 (1.3) 0 1 (1.6) 0
Nausea 5 (2.0) 14 (5.5) – – – –
Vomiting 2 (0.8) 15 (5.9) 1 (1.3) 0 – –
General disorders and All 11 (4.3) 3 (1.2) 3 (3.9) 0 2 (3.2) 0
administration site conditions
Infections and infestations All 10 (3.9) 1 (0.4) 3 (3.9) 0 2 (3.2) 0
Injury, poisoning, and All 8 (3.1) 0 1 (1.3) 0 – –
procedural complications
Investigations All 2 (0.8) 1 (0.4) 3 (3.9) 1 (1.3) 3 (4.8) 1 (1.6)
Hyperglycemia – – 2 (2.6) 0 – –
Metabolism and nutrition All 7 (2.8) 4 (1.6) 1 (1.3) 0 1 (1.6) 0
disorders
Musculoskeletal and All 11 (4.3) 0 1 (1.3) 0 1 (1.6) 0
connective tissue
disorders
Neoplasms benign, malignant,
and unspecified (including All 4 (1.6) 0 3 (3.9) 0 1 (1.6) 0
cysts and polyps)
Nervous system disorders All 17 (6.7) 8 (3.1) 5 (6.6) 0 7 (11.1) 0
Psychiatric disorders All 28 (11.0) 22 (8.7) 4 (5.3) 0 5 (7.9) 3 (4.8)
Anxiety 1 (0.4) 0 – – 2 (3.2) 0
Psychomotor 2 (0.8) 5 (2.0) 1 (1.3) 0 0 2 (3.2)
agitation
Renal and urinary disorders All 8 (3.1) 0 – – 1 (1.6) 0
Respiratory, thoracic, and All 10 (3.9) 0 2 (2.6) 0 – –
mediastinal disorders
Vascular disorders All 10 (3.9) 0 3 (3.9) 0 – –
–, not reported.
1.02–3.18, p = 0.04). No statistically significant differ-
ence was seen in the likelihood of premature study
discontinuation owing to a change in ADAS-cog/11
≥4 between treatment groups (HR 1.66, 95% CI
0.78–3.54, p = 0.19). The HR was similar for each anal-
ysis; therefore, this shows consistency across analyses.
Deterioration of ADAS-cog/11 was based on just
27 subjects who dropped out owing to ADAS-cog/11
≥4; therefore, the ADAS-cog analysis was underpow-
ered. Forty five subjects withdrew before they reached
a cognitive deterioration of ADAS-cog ≥4, so it was
not possible to know if these subjects would have been
eligible for the ADAS-cog/11 survival analysis. Thus,
although the recruitment target was met, the number of
subjects dropping out for other reasons was higher than
expected, therefore affecting the power of the study.
Subjects with a higher MMSE score at baseline
were more likely to respond to galantamine treatment
and were less likely to show cognitive decline. Also,
subjects who responded to treatment after 12 months
benefited from continuing treatment with galantamine.
Delaying cognitive deterioration can delay time to
nursing home placement (NHP) [5]. A recent study
found that the length of treatment with galantamine
was associated with a reduced risk of NHP; for each
year of treatment with galantamine, the risk of NHP
was reduced by 31% [5]. This, and the reduced burden
of care for informal caregivers should reduce associ-
ated healthcare costs.
Measuring cognitive functions over prolonged peri-
ods of time in patients with AD is particularly
challenging because of the declining health of subjects,
which leads to a large number of dropouts. The present
study accounted for this difficulty by using a with-
drawal design and measuring time to dropout, which
meant that there were no missing data. A weakness of
this study was that it was not sufficiently powered
for the ADAS-cog/11 survival analysis. Many sub-
jects dropped out before they reached a difference in
ADAS-cog/11 ≥4; only 27 subjects dropped out when
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looking at measured cognitive decline (difference in
ADAS-cog ≥4).
The withdrawal design of the trial could raise an
ethical issue as some subjects positively responding
to the drug were randomized to placebo treatment,
hence effective treatment was stopped. However, in
light of the lack of information in the literature at the
time of trial planning, this approach was considered
advisable in order to clarify the real efficacy of galan-
tamine in a long-term treatment perspective. All local
ethics committees of the 29 clinical centers gave their
formal approval to the design in consideration of the
importance of continuing the clinical development of
galantamine.
It was an unusual design feature that randomization
took place at the beginning of the open label phase
rather than the double blind phase; however, this does
not seem to have negatively affected the study, and the
subjects were still well balanced.
In addition, neuropsychiatric and behavioral scales
such as the Neuropsychiatric Inventory (NPI) and the
Alzheimer’s Disease Cooperative Study group – Activ-
ities of Daily Living (ADCS-ADL) scale were not
included in this study; however, they might have been
useful to include to assess the functional status of the
patients.
Data from this study has provided supporting evi-
dence that galantamine is well tolerated when used
for long term treatment, as seen in other studies
[6–8]. The tolerability of galantamine improved with
the duration of treatment. Many of the AEs seen in
this study were typical of those encountered after
administration of cholinesterase inhibitors. There were
more deaths in the galantamine group than in the
placebo group, but no deaths were considered to be
treatment related. These results should be interpreted
with caution as data were obtained from a small
sample size in a study with a withdrawal design.
Therefore, definite conclusions on the safety profile
of galantamine in this study cannot be made and
data from other studies should be considered for
safety and tolerability of galantamine. For example,
a meta-analysis of mortality data from double blind,
placebo controlled randomized trials and a recon-
tact study to collect longer term mortality data found
no evidence of increased risk of mortality associ-
ated with the use of galantamine in patients with AD
[9].
On the basis of the evidence from this study, and in
line with current guidelines [10], treatment should be
continued in patients with AD who benefit from galan-
tamine therapy, and interruption of therapy in specific
patients should be undertaken with caution. Treatment
should only be discontinued if the patient experiences
untoward effects.
In conclusion, subjects who responded to 12 months
of galantamine treatment benefited from continued
drug therapy for up to 36 months. Galantamine was
effective in delaying time to dropout due to any reason
or for lack of efficacy in subjects with mild to moderate
AD. Treatment was generally safe and well tolerated.
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